NUANCE BIOTECH INC
Shanghai, China (June 27, 2018)
Nuance Biotech, a China-based specialty pharmaceutical company, today announced Series B fundraising of US$20 million with additional capital US$15 million tied to its acquisition of new products, led by C-Bridge Capital, a private equity firm focused on development and commercialization opportunities within the growing Chinese healthcare market, and Neo Zhang, Managing Director of C-Bridge Capital, will join the board of Nuance. The Series B round prepares Nuance for the rapid expansion of portfolio of innovative pharmaceutical products, leveraging C-Bridge Capital’s extensive global network to help identify high-value licensing… (Read More)